How to order VABOMERE® for your institution

Order VABOMERE® (meropenem and vaborbactam) using standard ordering procedure through your specialty distributor

  • VABOMERE is a specialty distributor stocked product
  • Customers with specialty accounts can continue to order until 7pm ET and receive product the next business day. For special circumstances, you can receive an emergency order on a Saturday or Sunday. Please check with your specialty distributor for details
  • Download the Order Sheet for more information

VABOMERE comes in a box of 6 vials, the typical course of daily treatment*

How it’s supplied1:

VABOMERE is supplied as a white to light yellow sterile powder for constitution in single-dose, clear glass vials that contain 2 grams of VABOMERE. Each vial contains 1 gram of meropenem (equivalent to 1.14 grams of meropenem trihydrate), 1 gram of vaborbactam, and 0.575 gram of sodium carbonate.

ONE BOX is ONE DAY of treatment.*

VABOMERE 4 g (2 g meropenem and 2 g vaborbactam)

NDC NO.

70842‑0120‑06

Each vial contains VABOMERE 2 g (1 g meropenem and 1 g vaborbactam) for injection and is supplied in a box of 6 vials.

Typical full course of daily treatment for patients with eGFR ≥50 mL/min/1.73 m2. Additional dosing information for patients with renal impairment can be found in the Dosing section of this website.

DOWNLOAD ORDERING SHEET

VABOMERE Specialty Distributor Ordering Information:

Distributor Name Customer Service Phone Customer Service Email
AmerisourceBergen Specialty Distribution 800-746-6273 Asd.customerservice@asdhealthcare.com
Cardinal Health Specialty Pharmaceutical Distribution 855-855-0708 https://www.cardinalhealth.com/en/solutions/specialty-distribution-services.html
Curascript Customer Service 877-599-7748 Customer.Service@curascript.com
McKesson Plasma and Biologics 877-625-2566 mpborders@mckesson.com
McKesson Specialty Health 855-477-9800 mshcustomercare-mspl@mckesson.com
McKesson Specialty Health (oncology customers) 800-482-6700 oncologycustomersupport@mckesson.com
Morris & Dickson 800-388-3833 customerservice@morrisdickson.com

Billing and coding information for VABOMERE

Covers the coding requirements, coding systems, and their application when VABOMERE is administered

  • Lists ICD-10 codes and transition of care codes to facilitate timely claims processing and reduce the risk of denied claims
    –Includes the permanent J Code (J2186) for VABOMERE
  • Addresses coverage and payment information pertaining to Medicare, Medicaid, and commercial payers, in inpatient and outpatient settings, including long-term acute care and home infusion reimbursement
  • Includes sample CMS 1450 and CMS 1500 billing forms
  • See Coding and Billing Reference Guide for detail
DOWNLOAD CODING AND BILLING REFERENCE GUIDE

References: 1. VABOMERE [package insert]: Melinta Therapeutics, LLC.

INDICATION AND USAGE

VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE® and other antibacterial drugs, VABOMERE® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

VABOMERE® is contraindicated in patients with known hypersensitivity to any components of VABOMERE® (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.

Warnings and Precautions

  • Hypersensitivity reactions were reported in patients treated with VABOMERE® in the clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving therapy with beta-lactam antibacterial drugs. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam antibacterial drug. If an allergic reaction to VABOMERE® occurs, discontinue the drug immediately.
  • Seizures and other adverse Central Nervous System (CNS) experiences have been reported during treatment with meropenem, which is a component of VABOMERE®. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity.
  • Rhabdomyolysis has been reported with the use of meropenem, a component of VABOMERE® If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, discontinue VABOMERE and initiate appropriate therapy.
  • Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including VABOMERE®, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
  • The concomitant use of VABOMERE® and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. If administration of VABOMERE® is necessary, consider supplemental anticonvulsant therapy.
  • In patients with renal impairment, thrombocytopenia has been observed in patients treated with meropenem, but no clinical bleeding has been reported.
  • Alert patients receiving VABOMERE® on an outpatient basis regarding adverse reactions such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment.
  • Prescribing VABOMERE® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of drug-resistant bacteria.
  • As with other antibacterial drugs, prolonged use of VABOMERE® may result in overgrowth of nonsusceptible organisms.

Adverse Reactions

The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE® were headache, phlebitis/infusion site reactions, and diarrhea.

Please see full Prescribing Information.
Important Safety Information

INDICATION AND USAGE

VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.


Contraindications

VABOMERE® is contraindicated in patients with known hypersensitivity to any components of VABOMERE® (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.